Brief Overview of Current Treatment Landscape for 1L EGFRm NSCLC
Panelists discuss how the treatment landscape for EGFR-mutated lung cancer has evolved, with 3 strong options now available, including single-agent osimertinib and 2 combinations: osimertinib plus chemotherapy (FLAURA2) and amivantamab plus lazertinib (MARIPOSA), with the latter showing significant overall survival benefits.
EP: 1.Brief Overview of Current Treatment Landscape for 1L EGFRm NSCLC
EP: 2.Impressions of MARIPOSA Overall Survival and Potential Impact in Current SOC
EP: 3.Evaluating Chemotherapy-Free vs Chemotherapy-Containing Combos in First-Line EGFR-Mutated NSCLC: Pros and Cons
EP: 4.Decision-Making Factors in Choosing Combination Therapies in EGFR-Mutated NSCLC
EP: 5.Insights from MARIPOSA: Impressions of the Intracranial Data
EP: 6.Analysis of MARIPOSA & SKIPPirr Trials: Safety and Quality of Life
EP: 7.Assessing the Adverse Effect Profile of Ami-Laz in Comparison With Other Combination Therapies in EGFRm NSCLC
EP: 8.Looking Ahead and Key Takeaways in EGFRm NSCLC
Video content above is prompted by the following:
First-Line EGFRm NSCLC Treatment Landscape Overview
Current Treatment Options
The treatment landscape for EGFR-mutated (EGFRm) non–small cell lung cancer (NSCLC) has evolved significantly, with 3 strong first-line options now available:
- Osimertinib monotherapy: The established standard treatment option
- Osimertinib plus chemotherapy: Combination supported by the FLAURA2 trial data
- Amivantamab plus lazertinib: Recent combination showing significant survival benefits in the MARIPOSA trial
Recent Advances: MARIPOSA Trial Results
The MARIPOSA trial, a randomized phase 3 study, compared 3 treatment regimens:
- Amivantamab plus lazertinib
- Osimertinib (control arm)
- Lazertinib plus osimertinib
Key Findings:
- Significant overall survival (OS) benefit: HR of 0.75 for amivantamab plus lazertinib compared with osimertinib monotherapy
- Sustained survival advantage: Survival curves separating early and continuing to widen over time
- Potential median OS improvement: Mathematical modeling suggesting up to 12-month difference in median survival (though median not yet reached for the treatment arm)
- Impressive landmark data: Progressive improvement in survival difference at 24, 36, and 42 months
The amivantamab plus lazertinib combination represents a novel mechanism targeting both EGFR and c-MET receptors, providing a valuable new option for first-line treatment of EGFRm NSCLC.
The trial continues with follow-up for a 5-year landmark analysis, with current survival projections suggesting beyond 4 years of median OS for patients receiving the combination therapy.
Prolaris in Practice: Guiding ADT Benefits, Clinical Application, and Expert Insights From ACRO 2025
April 15th 2025Steven E. Finkelstein, MD, DABR, FACRO discuses how Prolaris distinguishes itself from other genomic biomarker platforms by providing uniquely actionable clinical information that quantifies the absolute benefit of androgen deprivation therapy when added to radiation therapy, offering clinicians a more precise tool for personalizing prostate cancer treatment strategies.
CCR Scores and Beyond: Precision Strategies for Treatment Intensification in Prostate Cancer
April 15th 2025Alvaro Martinez, MD discusses how emerging genomic risk stratification tools such as the clinical cell-cycle risk (CCR) score are transforming personalized prostate cancer treatment by enabling more nuanced assessments of metastasis risk and treatment intensification strategies beyond traditional NCCN risk groupings.
